Pharmacogenetics may influence the impact of inflammation on voriconazole trough concentrations. (August 2017)

• Record Type: Journal Article
• Authors: Gautier-Veyret, Elodie; Bailly, Sebastien; Fonrose, Xavier; Tonini, Julia; Chevalier, Simon; Thiebaut-Bertrand, Anne; Stanke-Labesque, Françoise
• Is Part Of: Pharmacogenomics. Volume 18:Number 12(2017)
• Page Start: 1119
• Page End: 1123
• Publication Date: 2017-08
• Subjects: CYP2C19 -- CYP3A4 -- inflammation -- pharmacogenetics -- therapeutic drug monitoring -- voriconazole; Pharmacogenomics -- Periodicals; 615.1
• DOI: 10.2217/pgs-2017-0054
• Languages: English
• ISSNs: 1462-2416

Abstract

How pharmacogenetics modulates the inhibitory effects of inflammation on voriconazole trough concentration (Cmin) remains unknown. In 29 recipients of allogeneic hematopoietic stem cell transplantation retrospectively studied, both a genetic score (which aggregated CYP2C19 and CYP3A genotypes) and inflammation significantly influenced voriconazole Cmin (n = 260). A trend toward (p = 0.03) a greater impact of inflammation in patients with the highest genetic score (corresponding to ultra-rapid metabolizers) was observed. Further researches are needed to confirm these data.